Figure 2

OS and DFS, and cumulative incidence of relapse and NRM related to BCR–ABL subtypes in 60 patients with Ph+ALL who underwent allo-HSCT in their first CR following imatinib-based therapy. (a) OS, (b) DFS, (c) cumulative incidence of relapse and (d) cumulative incidence of NRM.